Description
Penn Medicine Hypertension, Lipids, and Approaches to CV Pharmacologic Risk Reduction What’s New in 2022
Penn Medicine CV Pharmacologic Risk Reduction
Include: 13 videos + 16 pdfs, size: 3.02 GB
Date & Location
Friday, September 30, 2022, 7:45 AM – 2:00 PM, Virtual, Philadelphia, PA
Course Overview
CVD is the leading cause of death in the US. Hypertension and diabetes are among the foremost risk factors for the development of CVD, stroke, peripheral artery disease, and heart attack. This program will provide an overview of recent advances that target the underlying pathophysiology of cardiovascular disease. The focus of the program will be on the new guidelines for hypertension, DM and CKD and will discuss the advances in pharmacotherapeutics in these fields.
Target Audience
Penn Medicine CV Pharmacologic Risk Reduction
Specialties – FAMILY MEDICINE, FAMILY MEDICINE – Geriatric Medicine, INTERNAL MEDICINE, INTERNAL MEDICINE – Advanced Heart Failure and Transplant Cardiology, INTERNAL MEDICINE – Clinical Cardiac Electrophysiology, INTERNAL MEDICINE – Endocrinology, Diabetes and Metabolism, INTERNAL MEDICINE – Geriatric Medicine, INTERNAL MEDICINE – Interventional Cardiology, INTERNAL MEDICINE – Nephrology, INTERNAL MEDICINE – Sports Medicine, OBSTETRICS AND GYNECOLOGY, OBSTETRICS AND GYNECOLOGY – Maternal and Fetal Medicine, PREVENTIVE MEDICINE – Clinical Informatics, PUBLIC HEALTH AND GENERAL PREVENTIVE MEDICINE
Learning Objectives
After completing this activity, participants should be able to:
- Select appropriate medications to reduce adverse cardiovascular outcomes in high-risk and vulnerable populations
- Identify appropriate blood pressure goals and management in several special patient populations
- Review the controversies regarding the appropriate treatment of and management of pregnant patients at risk for CVD.
- Achieve competence in providing the best screening and treatment options for hypertension in patients with hyperlipidemia in young patients.
- Apply appropriate pharmacologic and non-pharmacologic approaches to cardiovascular risk prevention
Topics:
- BP Goals and Use of Thiazides in Advanced CKD.mp4
BP Goals and Use of Thiazides in Advanced CKD.pdf
BP Goals Management in Elderly (STEP Trial and SPRINT).mp4
BP Goals Management in Elderly (STEP Trial and SPRINT).pdf
BP22_Brochure_v4.pdf
Cholesterol.mp4
Cholesterol.pdf
Clinical Case Discussion FOUNDATIONS- REFRESHER OF THE CURRENT GUIDELINES.pdf
Clinical Case Discussion SPECIAL POPULATIONS.pdf
DM Weight loss.mp4
DM Weight loss.pdf
Hypertension.mp4
Hypertension.pdf
Lipid Management and Risk Assessment in Younger Patients.mp4
Lipid Management and Risk Assessment in Younger Patients.pdf
New Agents in Lipid Management.mp4
New Agents in Lipid Management.pdf
Non-steroidal MRAs in HTN, DM2, and CKD.mp4
Non-steroidal MRAs in HTN, DM2, and CKD.pdf
Peripartum CV Risk Reduction.mp4
Peripartum CV Risk Reduction.pdf
Polypill – Quad Study Combo Therapy for BP and Lipids.mp4
Polypill – Quad Study Combo Therapy for BP and Lipids.pdf
Population-Wide Effects and Local Public Health Efforts of Sodium Reduction.mp4
Population-Wide Effects and Local Public Health Efforts of Sodium Reduction.pdf
Update in Renal Denervation.mp4
Update in Renal Denervation.pdf
Weight Loss Strategies in Highly Comorbid Patients.mp4
Weight Loss Strategies in Highly Comorbid Patients.pdf
